- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00841477
An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users
January 10, 2017 updated by: National Institute on Drug Abuse (NIDA)
The goal of the proposed study is to use the HBV vaccine as a model for a future HIV vaccine trial, examining the efficacy of community-based outreach intervention as well as an accelerated vaccine schedule as a method for increasing acceptance/adherence with HBV vaccination protocols among not-in-treatment drug users.
This study will also examine the effect of HBV vaccination coupled with community-based outreach intervention on reducing the incidence of HIV, HBV and HCV infections and the frequency of needle use and sexual risk behaviors related to these viral transmissions.
A secondary purpose will be to assess the antibody response after HBV vaccination as a measurement of immunological response in drug users.
Study Overview
Status
Completed
Detailed Description
This project will evaluate an HBV vaccination program as a model for future HIV vaccine efficacy trials in a community-based study of drug users.
Two components will be analyzed in an effort to increase vaccine acceptance/adherence - behavioral intervention & an accelerated vaccine schedule.
The study also will examine the effect of these variables on risk behaviors and incidence of HIV, HBV, & HCV infections.
To accomplish these objectives, we propose a randomized behavioral intervention field trial.
We will enroll 1600 current cocaine or heroin users negative for HBV & HIV markers from two closely matched, low-income, high drug endemic communities in Houston.
All participants will be offered HBV vaccination and follow-up viral testing.
One community will be randomly assigned to receive an outreach behavioral intervention designed to increase vaccine awareness and vaccine compliance.
The other community will receive standard care.
Participants electing to be vaccinated will be randomized to either a 0,1,6 month or a 0,1,2, month vaccine schedule.
Groups will be followed for two years to determine rates of HBV vaccine acceptance/adherence to the 3-dose protocol.
We also will measure any changes in risk behaviors & incidence of HIV/HBV/HCV infections as well as HBV vaccine immune response, if vaccinated.
Drug users are the largest group of newly diagnosed HIV cases and so creating a model for an HIV vaccine's acceptance and adherence in this population is an important public health goal.
This study will serve as a model for future HIV vaccine trials and will provide information on the effectiveness of outreach programs for increasing immunization among drug users.
Unless an effective model based upon empirical experience is developed, any attempt to implement a HIV vaccination program among drug users is likely to be frustrated.
If HBV vaccination coupled with outreach intervention can reduce risk behaviors and decrease the incidence of HIV/HCV infection, then this study will have a tremendous impact on the current HBV/HIV/HCV prevention strategy.
Study Type
Interventional
Enrollment (Actual)
1260
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas-HSC at Houston, School of Public Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- using cocaine/heroin in last 7 days, age over 18 years old from two matched in population size, income and demographic communities, known with high rate of drug using and STD; competent to consent for urine drug screening and viral markers (anti-HIV, HBsAg/anti-HBs, anti-HCV) testing; those negative for HIV/HBV will be contacted for HB vaccination study.
Exclusion Criteria:
- age under 18 or not from the target communities, negative for urine drug test.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: A1
standard behavioral intervention, standard HB vaccine schedule (0,1,6month)
|
|
Active Comparator: A2
standard behavioral intervention, accelerated HB vaccine schedule (0,1,2month)
|
hepatitis B (HB) vaccine: Engerix-B (GlaxoSmithKline) (20 µg/dose) accelerated HB vaccine schedule (0,1,2 month),vs, standard HB vaccine schedule (0,1,6 m)
Other Names:
|
Active Comparator: B1
enhanced behavioral intervention, standard vaccine schedule
|
HB Vaccination Intervention consists of 4 sessions - Sessions 1, 2: at screening and enrollment after intake, vs regular risk reduction education Sessions 3, 4: coincide with the vaccination schedule ions 4 before 3rd dose
Other Names:
|
Active Comparator: B2
enhanced behavioral intervention, accelerated vaccine schedule (0,1,2MONTH)
|
hepatitis B (HB) vaccine: Engerix-B (GlaxoSmithKline) (20 µg/dose) accelerated HB vaccine schedule (0,1,2 month),vs, standard HB vaccine schedule (0,1,6 m)
Other Names:
HB Vaccination Intervention consists of 4 sessions - Sessions 1, 2: at screening and enrollment after intake, vs regular risk reduction education Sessions 3, 4: coincide with the vaccination schedule ions 4 before 3rd dose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
compliance (adherence) for 3 doses hepatitis vaccination
Time Frame: Jan, 2004 - June 2008
|
Jan, 2004 - June 2008
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
incidence of HIV and HCV infection and change of risk behaviors
Time Frame: Jan, 2004- June 2009
|
Jan, 2004- June 2009
|
immunological response
Time Frame: Feb 2004 - June 2008
|
Feb 2004 - June 2008
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Lu-Yu Hwang, MD, University of Texas-HSC at Houston
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Hwang LY, Grimes CZ, Tran TQ, Clark A, Xia R, Lai D, Troisi C, Williams M. Accelerated hepatitis B vaccination schedule among drug users: a randomized controlled trial. J Infect Dis. 2010 Nov 15;202(10):1500-9. doi: 10.1086/656776. Epub 2010 Oct 11.
- Tran TQ, Grimes CZ, Lai D, Troisi CL, Hwang LY. Effect of age and frequency of injections on immune response to hepatitis B vaccination in drug users. Vaccine. 2012 Jan 5;30(2):342-9. doi: 10.1016/j.vaccine.2011.10.084. Epub 2011 Nov 8.
- Shah DP, Grimes CZ, Brown E, Hwang LY. Demographics, socio-behavioral factors, and drug use patterns: what matters in spontaneous HCV clearance? J Med Virol. 2012 Feb;84(2):235-41. doi: 10.1002/jmv.22271.
- Grimes CZ, Hwang LY, Wei P, Shah DP, Volcik KA, Brown EL. Differentially regulated gene expression associated with hepatitis C virus clearance. J Gen Virol. 2013 Mar;94(Pt 3):534-542. doi: 10.1099/vir.0.047738-0. Epub 2012 Nov 14.
- Kamath GR, Shah DP, Hwang LY. Immune response to hepatitis B vaccination in drug using populations: a systematic review and meta-regression analysis. Vaccine. 2014 Apr 25;32(20):2265-74. doi: 10.1016/j.vaccine.2014.02.072. Epub 2014 Mar 12.
- Lu-Yu. Hwang*, Carolyn. Grimes "Human Immunodeficiency Virus, hepatitis B and C Virus infections among injecting and non-injecting drug users from inner city neighborhoods " Insight and Control of Infectious Disease in Global Scenario, Priti Kumar Roy (Ed), ISBN 978-953-51-0319-6, 2012, p45-60 InTech, Available from http://www.intechopen.com/articles/show/title/immunodeficiency-virus-hepatitis-b-and-hepatitis-c-virus-infections-among-injecting-and-non-injectin
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2004
Primary Completion (Actual)
June 1, 2007
Study Completion (Actual)
December 1, 2009
Study Registration Dates
First Submitted
February 10, 2009
First Submitted That Met QC Criteria
February 10, 2009
First Posted (Estimate)
February 11, 2009
Study Record Updates
Last Update Posted (Estimate)
January 11, 2017
Last Update Submitted That Met QC Criteria
January 10, 2017
Last Verified
April 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Disease Attributes
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Infections
- Communicable Diseases
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis C
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
Other Study ID Numbers
- DESPR DA017505
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infection
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Beckman Coulter, Inc.CompletedHIV I Infection | HIV-2 InfectionFrance
-
Allegheny Singer Research Institute (also known...Active, not recruitingHIV Infections | HIV-1-infection | HIV I InfectionUnited States
-
Rockefeller UniversityCompletedHIV Infection | Healthy Volunteers | HIV-1 InfectionUnited States
-
Erasmus Medical CenterRecruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
Erasmus Medical CenterActive, not recruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
AIDS Healthcare FoundationUniversity of California, Los AngelesCompleted
-
Merck Sharp & Dohme LLCCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedHIV-1 Infection | HIV Antibodies | Neutralizing Antibody | Viral Load | Monoclonal AntibodyUnited States
Clinical Trials on hepatitis B vaccine 3 dose schedule (0,1,2 month)
-
Jiangsu Province Centers for Disease Control and...Beijing Tiantan Biological Products Co., Ltd.Completed
-
PT Bio FarmaRS Umum Pusat Sanglah, DenpasarNot yet recruitingVaccine Adverse Reaction | Vaccine Reaction
-
Shanxi Medical UniversityCenters for Disease Control and Prevention, ChinaCompletedHepatitis B Vaccination
-
University of North Carolina, Chapel HillBurroughs Wellcome; The American Society of Tropical Medicine and HygieneCompletedHepatitis BCongo, The Democratic Republic of the
-
Suping WangCenters for Disease Control and Prevention, ChinaCompletedHepatitis B Vaccine
-
Suping WangCenters for Disease Control and Prevention, ChinaCompletedHepatitis B Vaccine
-
Shanxi Medical UniversityNot yet recruiting
-
African Malaria Network TrustLondon School of Hygiene and Tropical MedicineUnknownMalariaBurkina Faso
-
HenogenCompleted
-
African Malaria Network TrustLondon School of Hygiene and Tropical MedicineUnknown